High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

Parikh, PM; Powles, R; Treleaven, J; Helenglass, G; Gore, Martin; Rose, Michal G.; Talbot, D; Milan, S; Smith, C L; Pinkerton, Ross; Aboud, Hussain; Cavenagh, Jamie; Rowley, Mark; McElwain, T. J.; Hewetson, M

doi:10.1038/bjc.1990.387

Cited by 9 publications

(2 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…o.d. days 1–5 ( Parikh et al , 1990 ). Maintenance outpatient chemotherapy was given as 3, 4 and 5 d cycles of low‐dose cytosine arabinoside 60 mg/m 2 s.c. b.d.…”

Section: Case Reports and Family Datamentioning

confidence: 99%

Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation

et al. 1998

View full text Add to dashboard Cite

A kindred with familial acute myeloid leukaemia (AML) is described displaying the concept of anticipation which refers to increased disease severity and/or earlier age at onset with succeeding generations. The affected individual in the first generation was the father (aged 34 years at diagnosis) of two affected members of a single sibship (aged 24 and 25 years). The fourth patient is the son (aged 4 years) of one of these brothers in the second generation. The AML was of different subtypes and a karyotypic abnormality (del[6q]) was detected in one of three patients. The first-generation patient died during chemotherapy; the remaining three patients are in complete remission after chemotherapy and autologous bone marrow transplantation.

show abstract

“…o.d. days 1–5 ( Parikh et al , 1990 ). Maintenance outpatient chemotherapy was given as 3, 4 and 5 d cycles of low‐dose cytosine arabinoside 60 mg/m 2 s.c. b.d.…”

Section: Case Reports and Family Datamentioning

confidence: 99%

Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation

et al. 1998

View full text Add to dashboard Cite

show abstract

“…It has a different mechanism of action to other anti-leukaemic drugs and is well tolerated in combination [34]. Etoposide has been active in combination with standard- and high-dose cytarabine, doxorubicin, daunorubicin, idarubicin, vinblastine and amsacrine in refractory AML [35, 36, 37, 38, 39, 40]. …”

Section: Induction Therapymentioning

confidence: 99%

Approaches to Induction Therapy with Adult Acute Myeloid Leukaemia

Bishop

1998

Acta Haematol

View full text Add to dashboard Cite

Induction therapy of acute myeloid leukaemia (AML) with standard-dose chemotherapy will result in approximately 64% of patients achieving a complete remission (CR). New drugs which are active in induction therapy in randomised clinical trials are etoposide, idarubicin and high dose cytarabine. Intensification of induction treatment with etoposide or high-dose cytarabine does not appear to alter the CR rate but prolongs remission and has some impact on survival. High-dose cytarabine in induction combinations increase relapse-free survival compared to standard approaches. These induction results appear to parallel results obtained with post-remission therapies intensified with high-dose cytarabine. These studies provide clinical evidence that intensified induction with cytarabine in AML influences subsequent outcome but is more toxic, gives more profound myelosuppression post-remission and has benefit confined to younger patients.

show abstract

Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy

Whelan

Davis

Rohatiner

et al. 1992

Hematological Oncology

View full text Add to dashboard Cite

Thirty-four patients with refractory or recurrent high grade non-Hodgkin's lymphoma (NHL) or acute leukemia were treated with a combination of etoposide, 100 mg/m2 daily, and ara C, 1 g/m2 twice daily, for 5 days (VPARAC). This therapy was given in the anticipation that remissions thus achieved would be 'consolidated' with myeloablative therapy supported by bone marrow transplantation (BMT). The complete remission rate (CR) in patients with NHL was 3/18 (17 per cent) with partial responses (PR) seen in a further four patients, giving an overall response rate of 39 per cent. Four patients (three in CR, one in PR) proceeded to the planned consolidation treatment. Complete remission was achieved in 2/8 (25 per cent) patients with acute myelogenous leukemia (AML) and in 2/8 patients with acute lymphoblastic leukemia (ALL). Three of these patients subsequently had myeloablative consolidation therapy with BMT. There were four treatment-related deaths (NHL, two; AML, one; ALL, one). In poor risk patients with high grade NHL and acute leukemia, VPARAC is an effective remission induction programme in 21 per cent of patients. Seven of the original 34 patients received the intended 'curative' therapy, of whom only four are alive and well 1 year later.

show abstract

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

Cited by 9 publications

References 10 publications

Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation

Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation

Approaches to Induction Therapy with Adult Acute Myeloid Leukaemia

Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy

Contact Info

Product

Resources

About